

Disclosures

Personal Commercial (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------|---------------------------|--------------------|--|
| <i>Self</i> | | | |
| Abbott Laboratories | Speaker's Bureau | None (\$0) | Valvular Heart Disease |
| Edwards LifeSciences | Speaker's Bureau | Modest (< \$5,000) | Valvular Heart Disease |
| Medtronic | Consultant Fees/Honoraria | Modest (< \$5,000) | Valvular Heart Disease |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (8)

| Trial Name | Trial Sponsor | Trial Funding Source |
|--|------------------------------|----------------------|
| Amplatzer PFO Occluder post-marketing surveillance study | Abbott Medical Devices | |
| Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction | Ancora Heart Inc. | |
| BioVentrix Revivent TC™ System Clinical Study | bioventrix | |
| CPNS Pilot Study: Evaluation of Safety and Performance of the Cardiac Pulmonary Nerve Stimulation (CPNS) System in Patients With ADHF | Cardionomic Inc. | |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | Edwards Lifesciences | |
| SOS AMI | Idorsia Pharmaceuticals Ltd. | |
| MyLeukoMAP™ Genomic Survival Prediction Assay Pivotal Clinical Study | LeukoLifeDx Inc | |
| RELIEVE HF | V-WAVE LTD | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/8/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.